X

Vous n'êtes pas connecté

Rubriques :

Maroc Maroc - SMH.COM.AU - Business - 11/11/2025 03:04

NeuroScientific widens chronic bowel disease stem cell therapy program

NeuroScientific Biopharmaceuticals dosed a fourth Crohn’s patient with its StemSmart therapy ahead of phase 2 trials for its novel treatment of the debilitating bowel disease.

Articles similaires

Sorry! Image not available at this time

Relieving Financial Burden of Crohn's Disease on Young Patients

medindia.net - 08/Jan 10:23

bThirty five percent of young people who aged between 18-25 with medlinkInflammatory bowel disease (IBD)/medlink such as Crohn's disease and...

Sorry! Image not available at this time

CIRM awards $7.4 million to advance stem cell-based gene therapy for Friedreich's ataxia

news.medical.net - 08/Jan 17:24

The California Institute for Regenerative Medicine (CIRM) has awarded $7.4 million to support a University of California San Diego team developing a...

Sorry! Image not available at this time

Relieving Financial Burden of Crohn's Disease on Young Patients

medindia.net - 08/Jan 10:23

Young people with ulcerative colitis face insurance-driven treatment delays, demanding early support for patients to manage coverage, care and...

Sorry! Image not available at this time

MHRA authorises Nucala (mepolizumab) in the UK for the treatment of uncontrolled COPD of an eosinophilic phenotype for patients on triple therapy*

wn.com - 06/Jan 11:06

· The approval is based on two placebo-controlled phase 3 studies, which showed mepolizumab significantly reduced the annualised rate of...

Sorry! Image not available at this time

MHRA authorises Nucala (mepolizumab) in the UK for the treatment of uncontrolled COPD of an eosinophilic phenotype for patients on triple therapy*

wn.com - 06/Jan 11:06

· The approval is based on two placebo-controlled phase 3 studies, which showed mepolizumab significantly reduced the annualised rate of...

Sorry! Image not available at this time

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis

financialpost.com - 09/Jan 06:10

MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria...

Sorry! Image not available at this time

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis

financialpost.com - 09/Jan 06:10

MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria...

Sorry! Image not available at this time

GSK Announces Positive Results from B-Well 1 and B-Well 2 Phase III trials for Bepirovirsen, a Potential First-in-Class Treatment for Chronic Hepatitis B

drugs.com - 07/Jan 21:01

London, UK -- 07 January 2026 GSK plc (LSE/NYSE: GSK) today announced positive results from its two pivotal phase III trials, B-Well 1 [NCT05630807]...

Sorry! Image not available at this time

GSK Announces Positive Results from B-Well 1 and B-Well 2 Phase III trials for Bepirovirsen, a Potential First-in-Class Treatment for Chronic Hepatitis B

drugs.com - 07/Jan 21:01

London, UK -- 07 January 2026 GSK plc (LSE/NYSE: GSK) today announced positive results from its two pivotal phase III trials, B-Well 1 [NCT05630807]...

Sorry! Image not available at this time

Research points to major healthcare access challenges faced by young adults with IBD

news.medical.net - 06/Jan 14:09

The Crohn's & Colitis Foundation today revealed compelling new research pointing to major healthcare access challenges and financial burdens...

Les derniers communiqués